CATX beat EPS expectations by 20.23%
May 22, 2025, 10:32 PM
0.14%
What does CATX do
Perspective Therapeutics, based in Seattle, is a biotechnology company focused on developing radiopharmaceuticals for cancer treatment using the alpha-emitting isotope 212Pb. Their programs for melanoma and neuroendocrine tumors are in Phase I/IIa trials.
Perspective Therapeutics (CATX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Perspective Therapeutics's actual EPS was -$0.25, beating the estimate of -$0.31 per share, resulting in a 20.23% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.